人福医药集团股份公司 内控审计报告 大信审字[2025]第 2-00761 号 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haidian Dist. Beijing,China,100083 +86 (10) 82327668 www.daxincpa.com.cn 内部控制审计报告 大信审字[2025]第 2-00761 号 人福医药集团股份公司全体股东: 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查测 。 【 】 【 】 :1 星 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了人 福医药集团股份公司(以下简称人福医药)2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引 ...

国金证券股份有限公司 关于人福医药集团股份公司 2024 年度募集资金存放与使用 情况的专项核查意见 国金证券股份有限公司（以下简称"国金证券"或"独立财务顾问"）作为 人福医药集团股份公司（以下简称"人福医药"或"上市公司"）发行股份购买 资产并募集配套资金之独立财务顾问，根据《上市公司重大资产重组管理办法》 《上市公司并购重组财务顾问业务管理办法》等有关法律法规的要求，就人福医 药 2024 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可[2020]2562 号《关于核准人福医药集团 股份公司向李杰等发行股份购买资产并募集配套资金的批复》核准，上市公司向 李杰、陈小清、徐华斌发行股份购买相关资产，并向武汉当代科技产业集团股份 有限公司发行 89,047,195 股人民币普通股募集配套资金，募集配套资金金额为人 民币 999,999,999.85 元，扣除各项发行费用合计人民币 22,794,247.01 元，实际募 集资金净额人民币 977,205,752.84 元。上述资金到位情况已经大信会计师事务所 （特殊普 ...

人福医药集团股份公司 审 计 报 告 大信审字[2025]第 2-00760 号 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查影 报告编码:京25ER1X76F8 Room 2206 22/F Xuevuan International Towe No 1 Zhichun Road Haidian Dist Beijing China 100083 告 卡 报 田 大信审字[2025]第 2-00760 号 人福医药集团股份公司全体股东: 一、审计意见 我们审计了人福医药集团股份公司(以下简称"贵公司"或"人福医药公司")的财务 报表,包括 2024年12月 31日的合并及母公司资产负债表,2024年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 贵公司 2024 年 12月 31 日的合并及母公司财务状 ...

人福医药集团股份公司 2024 年度独立董事述职报告 刘林青 本人刘林青，作为人福医药集团股份公司（以下简称"公司"）独立董事，在 2024 年度严格按照《公司法》《上市公司独立董事管理办法》《上市公司治理准则》等法律 法规、规范性文件以及《公司章程》的规定和要求，认真、勤勉、独立的履行职责，积 极出席相关会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员会委员 的作用，切实维护了公司和全体股东的利益。现将本人 2024 年度履行独立董事职责情 况汇报如下： 一、独立董事的基本情况 刘林青，男，中共党员，管理学博士。现任武汉大学经济与管理学院教授，企业管 理和产业经济博士生导师，MBA 和 MPAcc 专业硕士生导师，兼任湖北京山轻工机械股 份有限公司独立董事、湖北文化旅游集团有限公司董事；2020 年 5 月至今任公司独立董 事。 充分沟通，提出了合理化建议，并以谨慎的态度行使表决权，维护公司整体利益和中小 股东的权益。本人对公司董事会各项议案及相关事项均表示赞成，无提出异议、反对或 弃权的情形。 （二）参加董事会专门委员会、独立董事专门会议工作情况 本人作为公司董事会审计委员会主任委员、董事会薪 ...

人福医药集团股份公司 2024 年度独立董事述职报告 张素华 本人张素华，作为人福医药集团股份公司（以下简称"公司"）独立董事，在 2024 年 度严格按照《公司法》《上市公司独立董事管理办法》《上市公司治理准则》等法律法规、 规范性文件以及《公司章程》的规定和要求，认真、勤勉、独立的履行职责，积极出席相 关会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员会委员的作用，切 实维护了公司和全体股东的利益。现将本人 2024 年度履行独立董事职责情况汇报如下： （二）参加董事会专门委员会、独立董事专门会议工作情况 本人作为公司董事会薪酬与考核委员会主任委员、董事会提名委员会委员，严格按照 有关法律法规、公司《董事会薪酬与考核委员会议事规则》《董事会提名委员会议事规则》 《独立董事专门会议工作制度》的有关要求，出席了相关会议。报告期内，本人共召集或 参加了董事会薪酬与考核委员会会议六次、董事会提名委员会会议一次、独立董事专门会 议两次，未委托出席或缺席任一次专门委员会会议。本人按照公司董事会各专门委员会议 事规则和《上市公司独立董事管理办法》的有关要求，认真研讨会议文件，为董事会科学 决策提供专业意见和 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 6,137,399,886.05, a decrease of 3.61% compared to CNY 6,367,371,531.88 in the same period last year[5] - Net profit attributable to shareholders increased by 11.09% to CNY 540,345,459.39 from CNY 486,392,045.37 year-on-year[5] - The basic earnings per share rose by 10.00% to CNY 0.33, compared to CNY 0.30 in the previous year[5] - Net profit for Q1 2025 reached ¥698,615,043.07, an increase of 7.77% from ¥648,188,795.48 in Q1 2024[24] - The profit attributable to shareholders of the parent company was ¥540,345,459.39, up 11.09% from ¥486,392,045.37 in the same period last year[24] - The total comprehensive income for Q1 2025 was CNY 19,507,763.31, down from CNY 1,046,940,693.40 in Q1 2024[36] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly, amounting to -CNY 336,779,640.63, compared to -CNY 179,495,908.96 in the same period last year[5] - The net cash flow from operating activities was -336,779,640.63 RMB, compared to -179,495,908.96 RMB in the previous period, indicating a decline in operational cash flow[27] - The company's cash and cash equivalents decreased to RMB 3,553,564,997.79 from RMB 3,915,043,500.34, representing a decline of approximately 9.2%[18] - The company's cash and cash equivalents at the end of the period were 2,502,199,269.15 RMB, down from 2,431,764,323.60 RMB, indicating a decrease in liquidity[28] - The net cash flow from operating activities for Q1 2025 was -CNY 368,333,839.68, compared to -CNY 58,027,536.85 in Q1 2024, reflecting worsening cash flow conditions[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 37,166,546,046.65, an increase of 1.80% from CNY 36,508,323,981.75 at the end of the previous year[6] - The company's current assets totaled RMB 20,412,196,364.83, compared to RMB 19,858,374,856.88 at the end of 2024, indicating an increase of about 2.8%[18] - Total liabilities stood at RMB 20,412,196,364.83, which is a significant portion of the total assets, indicating a leverage ratio that requires monitoring[19] - Total liabilities as of the end of the reporting period were ¥15,830,081,665.48, slightly up from ¥15,815,264,995.25 year-over-year[20] - The total liabilities rose to 6,205,988,301.04 RMB from 6,098,279,481.70 RMB, reflecting an increase in the company's obligations[32] Shareholder Information - The company has a total of 49,790 common shareholders at the end of the reporting period[10] - The largest shareholder, Wuhan Contemporary Science and Technology Industry Group Co., Ltd., holds 23.70% of the shares, totaling 386,767,393 shares[12] - Total equity increased to ¥21,336,464,381.17 from ¥20,693,058,986.50, reflecting a growth of 3.11%[20] Research and Development - Research and development expenses for Q1 2025 were ¥408,787,039.15, an increase of 17.00% compared to ¥349,340,705.03 in Q1 2024[23] - The company’s research and development expenses were CNY 888,348.41 in Q1 2025, down from CNY 2,578,537.90 in Q1 2024, indicating a reduction in R&D investment[36] Investment and Financing Activities - The company reported an investment income of ¥26,513,827.18, which is an increase from ¥16,870,550.16 in the previous year[23] - The company received CNY 1,056,000,000.00 in borrowings during Q1 2025, an increase from CNY 890,000,000.00 in Q1 2024[39] - The net cash flow from financing activities was 181,174,004.14 RMB, a recovery from -33,734,551.25 RMB in the previous period, showing improved financing conditions[28] Restructuring and Future Outlook - The company is undergoing a restructuring plan involving a potential change in control, with招商局创新科技（集团）有限公司 possibly becoming the largest shareholder, controlling 23.70% of the voting rights[14] - The company is expected to complete several regulatory procedures related to the restructuring, which may impact future operational strategies and market positioning[14]

Financial Performance - The company's operating revenue for 2024 reached ¥25.44 billion, representing a 3.71% increase compared to ¥24.52 billion in 2023[25]. - Net profit attributable to shareholders decreased by 37.70% to ¥1.33 billion in 2024 from ¥2.13 billion in 2023[25]. - The basic earnings per share for 2024 was ¥0.82, down 37.88% from ¥1.32 in 2023[26]. - The weighted average return on equity decreased by 5.65 percentage points to 7.67% in 2024 from 13.32% in 2023[26]. - Cash flow from operating activities increased by 10.01% to ¥2.16 billion in 2024 compared to ¥1.97 billion in 2023[25]. - The company's total assets as of the end of 2024 were ¥36.51 billion, a slight increase of 0.84% from ¥36.20 billion at the end of 2023[25]. - The net assets attributable to shareholders increased by 3.40% to ¥17.62 billion at the end of 2024 from ¥17.04 billion at the end of 2023[25]. - Non-recurring gains and losses for 2024 totaled ¥190.86 million, a decrease from ¥312.34 million in 2023[31]. - The company reported a net loss of ¥259.95 million in the fourth quarter of 2024, contrasting with profits in the first three quarters[29]. Dividend and Profit Distribution - The proposed cash dividend for 2024 is CNY 3.20 per 10 shares, totaling CNY 767,150,973.55, which accounts for 57.69% of the net profit attributable to shareholders[8]. - The company distributed cash dividends of CNY 244,838,664.75 in the first half of 2024[8]. - The company implemented a profit distribution plan for 2023 with a cash dividend ratio exceeding 35%, and plans to continue optimizing profitability and dividend policies for greater shareholder value[43]. - The board of directors has approved the proposal for the company’s future three-year profit distribution plan from 2024 to 2026[171]. Research and Development - The company applied for 449 patents during the reporting period, with 101 new patents granted, totaling 822 authorized patents[41]. - The company is focusing on R&D innovation, increasing investment in innovative drugs and specialty generic drugs, while enhancing quality management and cost control[55]. - The company’s R&D expenditure for 2024 reached RMB 162,967.89 million, representing a year-on-year increase of 5.73%[118]. - R&D expenditure accounted for 6.41% of the company's total revenue during the reporting period[118]. - The company has established R&D centers in Wuhan, Yichang, New Jersey, and St. Louis, employing 2,083 pharmaceutical R&D personnel[106]. - The company is focusing on expanding into unmet clinical needs in respiratory drugs, anti-tumor drugs, and autoimmune diseases[106]. Market Expansion and Product Development - The company launched approximately 20 new products during the reporting period, including new drugs for the nervous system and hormone drugs[40]. - The company’s U.S. generic drug business generated approximately 2 billion yuan in revenue during the reporting period[42]. - The company expanded its European market presence by acquiring drug approvals for several products through its subsidiary Paion Pharma[42]. - Revenue from the African market reached approximately 270 million yuan, driven by the company's initiatives in line with the Belt and Road Initiative[42]. - The company is actively expanding into overseas markets, including Europe, America, and emerging markets in Africa, Central Asia, and Southeast Asia[59]. Compliance and Regulatory Matters - The company has not received a conclusive opinion from the China Securities Regulatory Commission regarding the ongoing investigation for alleged information disclosure violations[7]. - The audit report issued by Da Xin Accounting Firm includes an emphasis on the significant uncertainty regarding the company's ability to continue as a going concern[7]. - The company has not violated decision-making procedures for providing guarantees[11]. - The company has been subject to administrative regulatory measures due to previous disclosure issues, impacting its compliance standing[185]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[166]. - The company has established a performance evaluation system for management, with a dedicated committee overseeing compensation standards[167]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors[169]. - The company actively engages with investors through various channels to address their needs and maintain transparency[170]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to CNY 42.65 million[183]. Financial Management and Investment - The company reported a total investment of RMB 54,924.36 million during the period, reflecting a 38.74% increase from RMB 39,589.19 million in the same period last year[130]. - The company has invested 20 million USD in interest rate swaps, with a fair value change loss of 481,980.84 USD during the reporting period[136]. - The company plans to consider a share buyback plan as part of its capital management strategy, which may enhance shareholder value[189]. - The company is implementing a comprehensive foreign exchange risk management mechanism to mitigate potential adverse impacts from currency fluctuations[161]. Challenges and Risks - The company faces risks from deepening medical reforms, which may increase competition and pressure on pricing and market share[156]. - The company recognizes the challenges in drug development due to high costs and long cycles, which may impact its R&D progress and profitability[159]. - The company will implement risk management mechanisms to address potential quality and production safety risks associated with its operations[158].

人福医药集团股份公司 2024 年度审计委员会履职情况报告 根据《上市公司治理准则》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》以及《人福医药集团股份公司章程》（以下简称"公司章 程"）《董事会审计委员会议事规则》《董事会审计委员会年报工作规程》的有关规定，作为 人福医药集团股份公司（以下简称"公司"）董事会审计委员会成员，我们本着勤勉尽责的原 则，充分发挥审计委员会的专业职能，切实有效地履行了相关职责。现就董事会审计委员会 2024 年度履职情况报告如下： 一、审计委员会基本情况 第十届董事会审计委员会现由独立董事刘林青先生、周睿先生及董事黄晓华先生组成，其 中主任委员刘林青先生系会计专业人士。 （1）刘林青，男，中共党员，管理学博士。现任武汉大学经济与管理学院教授，企业管理 和产业经济博士生导师，MBA 和 MPAcc 专业硕士生导师，兼任湖北京山轻工机械股份有限公 司独立董事、湖北文化旅游集团有限公司董事；2020 年 5 月至今任公司独立董事，2020 年 6 月 至今任第十届董事会审计委员会主任委员。 | | | | 允地反映公司在 | | --- | ...

2024 年度，人福医药集团股份公司（以下简称"公司"）监事会依照《公 司法》《证券法》《公司章程》《监事会议事规则》等相关规定和要求，依法独立 履行监督职能，对公司依法运作、决策程序、财务状况、定期报告、经营管理、 公司董事及高级管理人员履行职责情况等进行监督，切实维护公司及股东的合 法权益，现将 2024 年度监事会主要工作汇报如下： 一、监事会的基本情况 第十届监事会由 5 名监事组成，包括职工代表监事 2 名。公司第十届监事 会于 2023 年 5 月 29 日任期届满，鉴于换届工作尚在筹备中，为保证监事会相 关工作的连续性和稳定性，公司监事会延期换届。 二、监事会的工作情况 2024 年度监事会工作报告 报告期内，监事会成员积极列席公司董事会和股东大会会议，对会议程序、 决议事项、董事会对股东大会决议的执行情况、董事和高级管理人员的履职情 况等进行了监督和检查。监事会认为：公司严格依法经营，各项决策程序符合 《公司法》及《公司章程》的相关规定，决策合理、程序合法。公司董事、高 级管理人员能够按照相关法律、法规及《公司章程》的要求开展工作。公司重 视制度建设，并持续完善内部控制及管理制度，不断提升公司 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-054 号 人福医药集团股份公司 关于计提资产减值准备的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 （二）存货跌价损失 根据《企业会计准则第 1 号—存货》及公司会计政策，资产负债表日，存货按照 成本与可变现净值孰低计量，当期可变现净值低于成本时，提取存货跌价准备。以前 减记存货价值的影响因素已经消失的，存货跌价准备在原已计提的金额内转回。在确 定存货的可变现净值时，以取得的确凿证据为基础，同时考虑持有存货的目的以及资 产负债表日后事项的影响。公司及子公司对存货进行了清查和资产减值测试，本报告 期计提存货跌价损失 2,004.90 万元。 （三）固定资产、无形资产、开发支出减值损失 人福医药集团股份公司（以下简称"公司"或"人福医药"）于 2025 年 4 月 27 日召开第十届董事会第七十八次会议、第十届监事会第三十次会议，审议通过了《关 于计提资产减值准备的议案》，现将相关情况公告如下： 一、本次计提资产减值准备情况概述 根据《企业 ...